One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Avoidable mortality in the UK unlikely to change soon
doi : 10.1016/S1470-2045(23)00408-4
Volume 24, Issue 9, September 2023, Page 945
Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer
Dean A Fennell
doi : 10.1016/S1470-2045(23)00394-7
Volume 24, Issue 9, September 2023, Pages 946-947
SERDs for primary breast cancer
*Masakazu Toi, Tomoyuki Aruga
doi : 10.1016/S1470-2045(23)00291-7
Volume 24, Issue 9, September 2023, Pages 947-949
Combined gene therapies for high-grade glioma
Joshua D Bernstock, Alexander Ling, *E Antonio Chiocca
doi : 10.1016/S1470-2045(23)00389-3
Volume 24, Issue 9, September 2023, Pages 949-950
Gauging radiotherapy resources in South America and the Caribbean
Kellie Alleyne-Mike
doi : 10.1016/S1470-2045(23)00343-1
Volume 24, Issue 9, September 2023, Pages 951-952
Precision medicine for children with cancer
Ian F Tannock
doi : 10.1016/S1470-2045(23)00386-8
Volume 24, Issue 9, September 2023, Pages 952-954
Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy
Elif Hindié
doi : 10.1016/S1470-2045(23)00360-1
Volume 24, Issue 9, September 2023, Page e356
Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy – Author's reply
Binghe Xu
doi : 10.1016/S1470-2045(23)00361-3
Volume 24, Issue 9, September 2023, Page e357
Incorporating absolute effects to enrich interpretation of findings from meta-analyses
Jing Wu, Shitong Xie, Xiaoning He, Tianqi Hong, Liang Yao
doi : 10.1016/S1470-2045(23)00384-4
Volume 24, Issue 9, September 2023, Page e358
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply
Claire Petit, Jean-Pierre Pignon, *Pierre Blanchard
doi : 10.1016/S1470-2045(23)00402-3
Volume 24, Issue 9, September 2023, Page e359
Cancer research funding and care in the Philippines: gaps and ways forward
Katrina T Feliciano, Ullma Carmelene Demfre P Lindo, Althea Nicole P Tanedo, Dianne Camille A Gaspar, *Jake Bryan S Cortez
doi : 10.1016/S1470-2045(23)00356-X
Volume 24, Issue 9, September 2023, Page e360
Correction to Lancet Oncology 2023; 24: 855–67
doi : 10.1016/S1470-2045(23)00392-3
Volume 24, Issue 9, September 2023, Page e361
Correction to Lancet Oncol 2023; published online July 27. https://doi.org/10.1016/S1470-2045(23)00381-9
doi : 10.1016/S1470-2045(23)00383-2
Volume 24, Issue 9, September 2023, Page e361
Africa needs to boost HPV vaccine uptake to stem rise in cervical cancer
Kathryn Senior
doi : 10.1016/S1470-2045(23)00380-7
Volume 24, Issue 9, September 2023, Page 955
The global preventable cost of cancer drug wastage
Vijay Shankar Balakrishnan
doi : 10.1016/S1470-2045(23)00381-9
Volume 24, Issue 9, September 2023, Page 956
WHO's ninth report on the global tobacco epidemic
Udani Samarasekera
doi : 10.1016/S1470-2045(22)00341-2
Volume 24, Issue 9, September 2023, Page 957
Italy helps in Lebanon's cancer drug crisis
Manjulika Das
doi : 10.1016/S1470-2045(22)00788-4
Volume 24, Issue 9, September 2023, Page 958
A legacy of war: cancer care fragmentation in Iraq
Vijay Shankar Balakrishnan
doi : 10.1016/S1470-2045(23)00398-4
Volume 24, Issue 9, September 2023, Page 959
Improved cancer coverage for firefighters in Western Australia
Elizabeth Gourd
doi : 10.1016/S1470-2045(23)00399-6
Volume 24, Issue 9, September 2023, Page 960
Cancer risk estimates for US EPA-approved alternative plastic-based fuel cause alarm
Bryant Furlow
doi : 10.1016/S1470-2045(23)00400-X
Volume 24, Issue 9, September 2023, Page 961
Gynaecological cancer waiting times in Northern Ireland
Priya Venkatesan
doi : 10.1016/S1470-2045(23)00401-1
Volume 24, Issue 9, September 2023, Page 962
Medically assisted dying and cancer: a complex issue
Kathryn Senior
doi : 10.1016/S1470-2045(23)00409-6
Volume 24, Issue 9, September 2023, Page e362
NICE approval of AI technology for radiotherapy contour planning
Emma Wilkinson
doi : 10.1016/S1470-2045(23)00410-2
Volume 24, Issue 9, September 2023, Page e363
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies
*Mark P Lythgoe, Richard Sullivan, Sarah Blagden
doi : 10.1016/S1470-2045(23)00218-8
Volume 24, Issue 9, September 2023, Pages 963-966
Treatment-related mortality in children with cancer in low-income and middle-income countries: a systematic review and meta-analysis
Bella S Ehrlich, Michael J McNeil, Linh T D Pham, Yichen Chen, Jocelyn Rivera, Carlos Acuna, Liz Sniderman, Firas M Sakaan, Alejandra Mendez Aceituno, Cesar A Villegas, Lisa M Force, Nancy S Bolous, Parima P Wiphatphumiprates, Jeremy S Slone, Angela K Carrillo, Srinithya R Gillipelli, Caitlyn Duffy, Anita V Arias, Meenakshi Devidas, Carlos Rodriguez-Galindo, Sheena Mukkada, Asya Agulnik
doi : 10.1016/S1470-2045(23)00318-2
Volume 24, Issue 9, September 2023, Pages 967-977
Effect of paediatric early warning systems (PEWS) implementation on clinical deterioration event mortality among children with cancer in resource-limited hospitals in Latin America: a prospective, multicentre cohort study
Asya Agulnik, Hilmarie Muniz-Talavera, Linh T D Pham, Yichen Chen, Angela K Carrillo, Adolfo C?rdenas-Aguirre, Alejandra Gonzalez Ruiz, Marcela Garza, Tania Maria Conde Morelos Zaragoza, Dora Judith Soberanis Vasquez, Alejandra Méndez-Aceituno, Carlos Acu?a Aguirre, Yvania Alfonso Carreras, Shillel Yahamy Alvarez Arellano, Leticia Aradi Andrade Sarmiento, Rosario Batista, Erika Esther Blasco Arriaga, Patricia Calderon, Mayra Chavez Rios, Mar?a Eugenia Costa, Rosdali D?az-Coronado, Ever Amilcar Fing Soto, Wendy Cristhyna G?mez Garc?a, Martha Herrera Almanza, Maria Susana Juarez Tob?as, Esmeralda Mercedes Le?n L?pez, Norma Araceli L?pez Facundo, Ruth Angelica Martinez Soria, Kenia Miller, Scheybi Teresa Miralda Méndez, Lupe Nataly Mora Robles, Natalia del Carmen Negroe Ocampo, Berenice Noriega Acu?a, Alejandra Osuna Garcia, Carlos M Pérez Alvarado, Clara Krystal Pérez Fermin, Estuardo Enrique Pineda Urquilla, Carlos Andrés Portilla Figueroa, Ligia Estefan?a R?os Lopez, Jocelyn Rivera Mijares, Ver?nica Soto Ch?vez, Jorge Iv?n Suarez Soto, Juliana Teixeira Costa, Isidoro Tejocote Romero, Erika Elena Villanueva Hoyos, Marielba Villegas Pacheco, Meenakshi Devidas, Carlos Rodriguez-Galindo, on behalf of the EVAT Study Group
doi : 10.1016/S1470-2045(23)00285-1
Volume 24, Issue 9, September 2023, Pages 978-988
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Mustafa ?zgüro?lu*, Saadettin Kilickap*, Ahmet Sezer, Mahmut Gümü?, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, Irfan Cicin, Gwo Fuang Ho, Yaroslav Kulyaba, Kasimova Zyuhal, Roxana-Ioana Scheusan, Marina Chiara Garassino, Xuanyao He, Manika Kaul, Emmanuel Okoye, Yuntong Li, Siyu Li, Jean-Francois Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel
doi : 10.1016/S1470-2045(23)00329-7
Volume 24, Issue 9, September 2023, Pages 989-1001
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromir Roubec, Lubos Petruzelka, Libor Havel, Sujith Kalmadi, Jeffrey Ward, Zoran Andric, Thierry Berghmans, David E Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Christian Rolfo, Wallace Akerley, Michael Eaton, Mussawar Iqbal, Corey Langer, on behalf of the LUNAR Study Investigators
doi : 10.1016/S1470-2045(23)00344-3
Volume 24, Issue 9, September 2023, Pages 1002-1017
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial
Usha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, Andy Ryan, Naveena Singh, Ranjit Manchanda, Jatinderpal K Kalsi, Robert Woolas, Rupali Arora, Laura Casey, Anne Dawnay, Aarti Sharma, Karin Williamson, Sophia Apostolidou, Lesley Fallowfield, Alistair J McGuire, Stuart Campbell, Steven J Skates, Ian J Jacobs, Mahesh K B Parmar
doi : 10.1016/S1470-2045(23)00335-2
Volume 24, Issue 9, September 2023, Pages 1018-1028
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
Sara A Hurvitz, Aditya Bardia, Vanesa Quiroga, Yeon Hee Park, Isabel Blancas, José Luis Alonso-Romero, Aleksandr Vasiliev, Hryhoriy Adamchuk, Marcelo Salgado, Denise A Yardley, Oleksandr Berzoy, Pilar Zamora-Au??n, David Chan, Gonzalo Spera, Cloris Xue, Erika Ferreira, Tanja Badovinac Crnjevic, Pablo Diego Pérez-Moreno, Vanesa L?pez-Valverde, Jutta Steinseifer, Tharu M Fernando, Heather M Moore, Peter A Fasching, on behalf of the coopERA Breast Cancer study group*
doi : 10.1016/S1470-2045(23)00268-1
Volume 24, Issue 9, September 2023, Pages 1029-1041
Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial
Yoshie Umemura, Daniel Orringer, Larry Junck, Maria L Varela, Molly E J West, Syed M Faisal, Andrea Comba, Jason Heth, Oren Sagher, Denise Leung, Aaron Mammoser, Shawn Hervey-Jumper, Daniel Zamler, Viveka N Yadav, Patrick Dunn, Wajd Al-Holou, Todd Hollon, Michelle M Kim, Daniel R Wahl, Sandra Camelo-Piragua, Andrew P Lieberman, Sriram Venneti, Paul McKeever, Theodore Lawrence, Ryo Kurokawa, Karen Sagher, David Altshuler, Lili Zhao, Karin Muraszko, Maria G Castro, Pedro R Lowenstein
doi : 10.1016/S1470-2045(23)00347-9
Volume 24, Issue 9, September 2023, Pages 1042-1052
Financial hardship in families of children or adolescents with cancer: a systematic literature review
Julie Ritter, Savannah Allen, Phillip D Cohen, Andrés Felipe Fajardo, Kelsey Marx, Patr?cia Loggetto, Carmen Auste, Hedley Lewis, Karla Em?lia de S? Rodrigues, Sharmeen Hussain, Ayomide Omotola, Nancy S Bolous, Harsha Thirumurthy, Beverley M Essue, Eva Steliarova-Foucher, I-Chan Huang, Filip Meheus*, Nickhill Bhakta
doi : 10.1016/S1470-2045(23)00320-0
Volume 24, Issue 9, September 2023, Pages e364-e375
Radiotherapy resources in Latin America and the Caribbean: a review of current and projected needs based on International Atomic Energy Agency data
May Elbanna, Yaroslav Pynda, Oleksandr Kalinchuk, Arthur Rosa, May Abdel-Wahab
doi : 10.1016/S1470-2045(23)00299-1
Volume 24, Issue 9, September 2023, Pages e376-e384
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?
Allan Cramer, Freja K H S?rup, Hanne R Christensen, Tonny S Petersen, Kristian Karstoft
doi : 10.1016/S1470-2045(23)00357-1
Volume 24, Issue 9, September 2023, Pages e385-e394
Choriocarcinoma masquerading as pulmonary embolism in a patient with a history of tuberculosis
Guan-Lin Dai*, Yi-Cheng Wu*, Dan-Qing Wang
doi : 10.1016/S1470-2045(23)00323-6
Volume 24, Issue 9, September 2023, Page e395
